Applied Filters
Collegium settles patent dispute with Teva
Massachusetts-based Collegium Pharmaceutical has reached a settlement agreement with Teva, resolving its patent litigation over pain medication.
Janssen sues Mylan to block generic of schizophrenia drug
A Johnson & Johnson company, Janssen Pharmaceuticals, is seeking a court order blocking Mylan from making copies of its schizophrenia treatment, Invega Trinza, until its patent expires in 2036.
Bausch Health settles with Sun Pharma
Canada-based Bausch Health has dropped its litigation against Indian generic maker Sun Pharma as part of a settlement agreement.
BMS and Dr Reddy’s settle Revlimid suit with generics licence
Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid.
Gilead accused of illegally paying to delay HIV drug competition
Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.
Biogen loses another battle over MS drug patent
In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.
EPO revokes Copaxone patent, clears path for Mylan
The European Patent Office has invalidated and revoked a patent related to Teva’s multiple sclerosis drug Copaxone, in a win for Mylan.
Orexo sues Sun Pharma over opioid dependence generic
Swedish pharmaceutical company Orexo has taken India-based Sun Pharmaceutical to court in the US, over its plans to launch a generic version of Orexo’s opioid dependence treatment.
Judge gives initial approval to Actavis $20m antitrust deal
A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.
Ruling opens door for Noven’s oestrogen patch generics
In a victory for pharmaceutical company Amneal, a Delaware court has invalidated claims of three patents covering Noven Pharmaceuticals’ Minivelle oestrogen product.
